Since the recent introduction of a drug regimen containing 2 mg of the antiandrogen cyproterone acetate and 50 [ig ethinyloestradiol At six months the acne (as assessed by overali grade) had improved by 68% in the antibiotic treated group and by 74% in the oestrogen-cyproterone treated group. The group given a combination of both agents improved by 82%, which was significantly better (p<0025) than the improvement in the tetracycline treated patients. No significant difference was found between the groups given oestrogen-cyproterone alone and the combined treatment. The sebum excretion rate was suppressed by 25% in the patients in both groups receiving oestrogencyproterone but not in the group given antibiotics alone.
Introduction
Interest in the hormonal treatment of acne in women has been present since the sebaceous gland was found to be sensitive to androgens.' Oestrogens have been used effectively to treat acne but the dose required causes unacceptable side effects.2 Plainly, the ideal hormonal treatment would be one that affected only the skin, but no successful topical hormonal treatment is yet available. Oral and topical antiandrogenic treatments have been tried since Neumann and Elger first reported the effect of cyproterone acetate on mouse sebaceous glands.' In addition to being antiandrogenic, cyproterone acetate is progestogenic, such that in combination with oestrogen it provides contraceptive cover on a par with conventional combined oral contraceptives and has been used extensively in Europe. In the treatment of acne and related conditions it was given initially as the so called reverse sequential regimetx of Hammerstein and Cupceancu,4 when 50-200 mg cyproterone acetate daily for 10 days of the menstrual cycle was combined with [tg ethinyloestradiol given daily for 21 days of the cycle. More recently a preparation containing 2 mg cyproterone acetate and 50 [ig ethinyloestradiol (Diane) has been introduced as useful for the treatment of acne in women. In particular it is not known how this treatment compares with antibiotic treatment of acne. We set up a study to examine this point. Furthermore, as a combination treatment of the oestrogen-cyproterone preparation and antibiotics may be seen as possibly superior to a single entity this was compared as well. Women who had already tried antibiotics for their acne were chosen for a double blind randomised study. Oestrogen-cyproterone and antibiotic treatment influence different aetiological factors of acne and so the effect on sebum excretion and surface bacteria was assessed.
Patients and methods
We recruited 92 women aged 16- Rises and falls were also considered, since an apparent lack of change in a mean or median may be the result of large variations in counterbalancing directions, and this was done using the sign test.
Results
The numbers recruited for the three groups starting the trial were uneven because of an error of randomisation. The -Surprisingly, the antibiotic treated group showed an increase of the order of 7-13% in the sebum excretion rate, this being significant only at the end of the second month. Both oestrogencyproterone treated groups showed a significant reduction in sebum excretion at two, four, and six months. Maximum suppression of 26-9% in the group given the oestrogen-cyproterone preparation alone was seen by four months, and the combined treatment produced suppression of23-7% at six months. The effects of both hormonal regimens were significantly different from that of tetracycline alone (p<0-001), and at two months patients given oestrogen-cyproterone alone showed greater suppression of their sebum excretion than that achieved by the combined treatment (p<0 05).
Bacteriology-None of the treatments caused a significant reduction in the density of micrococcaceae on cheek skin. Both antibiotic regimens achieved a significant reduction in counts of propionibacteria of the order of 1 log cycle, but there was no significant difference between these treatments in the reductions caused (fig 6) .
Relapse data-Although not part of the original protocol, we followed up where possible those patients who could attend two months after stopping treatment. We were able to investigate 20 (80%) of the 25 patients given the combined treatments, 14 (67%) of the 21 given the oestrogen-cyproterone preparation alone, and 9 (56%) of the 16 given the antibiotic. Counts of inflamed and non-inflamed lesions showed no change; the improved overall grade was maintained in the hormonal treatment groups but the tetracycline group showed a relapse of their acne (fig 1) . Intergroup analyses showed that the antibiotic treated group fared significantly less well than patients given the combined regimen (p<0005); on the face improvement was maintained best by both the combined treatment group (p<0-001) and the group given the oestrogen-cyproterone preparation alone (p<0025) (fig 1) . The sebum excretion rate returned towards pretreatment values after both regimens of oestrogen-cyproterone ( fig 5) .
Discussion
This study confirmed several predicted results. It showed the benefit of tetracycline alone and of the oestrogen-cyproterone preparation alone. There are few studies showing long term benefit of oral tetracycline taken over six months.'2 Most are of shorter duration, usually three or four months or less. This study showed that with tetracycline continuing improvement was seen at two, four, and six months as assessed by the overall grades. Spot counts suggested that a steady state ofimprovement occurred between four and six months, but the discrepancy between grade and counts may be explained by the observation that inflamed acne lesions show various intensities of inflammation.8 In this study we did not distinguish between the more active inflamed and less active inflamed lesions. Clinical studies with oestrogen-cyproterone preparation using less refined assessment techniques have shown that improvement is maintained over a six month treatment period,6 and our findings support this. As with tetracycline alone, oestrogencyproterone acetate produced a maintained improvement over the second, fourth, and sixth months. There have been no other studies to show whether adding antibiotics brings greater benefit. Both drugs work in acne through different mechanisms. Oestrogencyproterone reduces the sebum excretion rate'"; antibiotics can affect the function of Propionibacterium acnes'4 and probably affect the host inflammatory mechanisms. It seemed likely that there may be synergism between the oestrogen-cyproterone preparation and tetracycline. This study, however, showed limited clinical benefit of the drug combination.
Our study produced a few unexpected results. The tetracycline treated group showed an overall increase of the sebum excretion rate of the order of 7-13%, just reaching significance at two months.
Other studies have failed to show an effect of antibiotics on sebum excretion.5 Our observation was unlikely to be a technical error since the patients started the treatment at different points in time and other studies carried out concurrently did not give any unusual results. The effect of another antimicrobial agent, benzoyl peroxide, on the sebum excretion rate is controversial'"'7 but in our laboratory we find that it increases the rate by 22%. 8 There is indirect evidence that ductal cornification is under hormonal control,20 and as oestrogen-cyproterone significantly reduces non-inflamed lesions it is likely that it must reduce ductal cornification; whether this is a direct or indirect effect is uncertain. In our study, although antibiotics did significantly reduce the counts of propionibacteria, the oestrogen-cyproterone preparation alone had no such effect and so an indirect effect of this agent on bacteria in reducing comedogenesis is most unlikely.
There are also few clinical or laboratory studies reporting events after stopping treatment. With the exception of isotretinoin24-2t all acne treatments fail adequately to maintain improvement once they are stopped. In our study follow up was for only two months. Assessment of total and facial grades indicated that both hormonal treatment groups fared better than the group given the antibiotic alone.
Side effects occurred in all groups and, although responsible for some withdrawals, they were not a serious problem for the patients. Side The term chronic bronchitis has been criticised because it is associated with hypersecretion of mucus rather than bronchial inflammation. This study was designed to establish the presence or absence of clinical chronic bronchitis and measure pulmonary function in 45 patients about to undergo resection of the lung. The condition in the cartilaginous and small airways and the severity of the emphysema were then measured in the resected specimen. The results from 20 patients who had clinical chronic bronchitis were compared with those in 25 patients who did not. The data show that patients with chronic bronchitis had greater inflammation (a) on mucosal surfaces (p<005) of all bronchi larger than 2 mm luminal diameter and (b) around glands (p<0005) and gland ducts (p<O05) in bronchi larger than 4 mm diameter. A variable degree of inflammation was present in the submucosa of smaller bronchi. The groups had equivalent proportions of mucous glands and Reid's indices in central airways, and no differences were noted in measurements of pulmonary function, condition of small airways, or emphysema. These data show that the term chronic bronchitis is justified by inflammation of cartilaginous airways and suggest that this abnormality may be the cause of the chronic productive cough.
Introduction
The Ciba Guest symposium of 1959 defined chronic bronchitis as "the condition of subjects with chronic or recurrent excessive mucus secretion in the bronchial tree."' As the diagnostic criterion is clinical the relation of hypersecretion of mucus to a condition in the airways in chronic bronchitis has been a source of controversy. Reid described an index of bronchial gland enlargement which she thought correlated with the amount of sputum produced.2 Subsequent studies showed that this index was normally distributed without a clear separation between the bronchitic and nonbronchitic groups.36 Although chronic bronchitis implies inflammation, the absence of documented inflammation of airways in these cases has recently led to objection to the term bronchitis.'
The common association of chronic bronchitis and the chronic limitation of airflow led early workers to assume that hypersecretion of mucus resulted in the limitation of airflow.89 Recent epidemiological studies, however, have suggested that chronic bronchitis and chronic limitation of airflow should be considered as separate entities rather than as manifestations of a single disease. "''3 The site of increased airway resistance in patients with chronic limitation of airflow has been shown to be the small conducting airways,'4 where the obstruction appears to be due to an inflammatory process. [15] [16] [17] [18] [19] [20] This study examines the nature of the condition in the central airways in patients with chronic bronchitis and determines its relation to the condition in the peripheral airways.
Patients and methods
We studied 45 patients admitted to this hospital for resection of an upper lobe (n=40) or lung (n=5) for, in most cases, bronchial carcinoma. Informed consent was obtained in all cases. A modified questionnaire by the British Medical Research Council was used to assess their exposure to cigarettes, cough, and history of sputum. To examine the differences in condition of airways and function of lungs between patients with chronic bronchitis and those without the patients were divided into two groups:
